Intelligence

Home / Intelligence

Type
  • All
  • Blog
  • Briefs
  • Case Studies
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Featured Topic
  • All
  • AIML
  • Analytics
  • APAC
  • Benchmarking
  • Biosimilars
  • CAR-T
  • Cell and Gene Therapy
  • Commercial Operations
  • Competitive Intelligence
  • Contract Analytics
  • Corporate Strategy
  • COVID-19
  • Data Management
  • Digital Therapeutics
  • Diversity
  • Emerging Life Sciences
  • Europe
  • Evidence Strategy (HEOR)
  • Field Force
  • Forecasting
  • Generative AI
  • Incentive Compensation
  • Inflation Reduction Act
  • Insights
  • International
  • LatAm
  • Launch and Brand Excellence
  • Learning and Development
  • Market Research
  • Marketing
  • MedTech
  • New Product Planning
  • NRDL
  • Omnichannel
  • Oncology
  • Patient Centricity
  • Patient Finding
  • Patient Services
  • Performance Tracking
  • Pricing and Access
  • Product Demos
  • Rare Disease
  • Real-World Evidence
  • Scientific Publications
  • Talent Acquisition and Retention
  • United States
  • Value Communication
Search
Medical stethoscope and piggy bank on a US of America flag, banner.

Webinars

Looking Ahead to the November Election and Beyond

August 14, 2024 | 1:00 - 2:00 PM ET

As healthcare policy and the access landscape evolve, biopharma companies face challenges in navigating this ever-changing space. To help organizations prepare for and adapt to these changes, Trinity Life Sciences is offering a new webinar series, The Next Era in U.S. Healthcare Policy & Access. Join us for the first webinar in the series, Looking Ahead to the November Election and Beyond.

Sign Up Now

Scientific Publications

Risk Factors Associated with Recurrence and Corticosteroid-Associated Adverse Events in Patients with Recurrent Pericarditis

Recurrent pericarditis (RP) occurs in up to 30% of acute pericarditis patients with some experiencing multiple recurrences and/or complications. Treating RP with corticosteroids can increase adverse events, risk of recurrence, and potentially healthcare resource utilization. This retrospective study examined risk factors for recurrence and corticosteroid-related adverse events (CS-AEs) among RP patients. Authors Schwier NC, Luis SA, Hu X, Athavale A, Skaar J, Magestro M, Lim-Watson M Journal ISPOR Meeting 2021 View publication…

Read Now

Scientific Publications

Clinical and Economic Impact of Primary Hyperoxaluria: A Retrospective Claims Analysis

Primary hyperoxalurias (PH; types 1, 2, and 3) are rare genetic disorders resulting in the overproduction of oxalate in the liver and that manifest in renal complications. This study sought to quantify the healthcare resource utilization (HCRU), costs, and clinical characteristics of PH patients. Authors Bernd Hoppe, Abigail Silber, Gavin Miyasato, Tom Koenig, Jeffrey Skaar, Craig Langman Journal American Society of Nephrology; ASN Kidney Week 2020 View publication…

Read Now

Scientific Publications

Effect of New-Onset Gout on Kidney Transplant Outcomes: A Retrospective Cohort Analysis of the United States Renal Data System

This investigation assessed if the development of new-onset gout after KT was an independent risk factor for loss of graft function, as assessed by the need for maintenance hemodialysis following KT. Authors J. Li, D. Yin, M. Brigham, B. Lamoreaux, J. Kent, M. Francis-Sedlak, R. Johnson, N. Hadker, K. Francis, H. Sanchez, G. Miyasato Journal EULAR 2020 View publication…

Read Now

Scientific Publications

The Burden of Familia Chylomicronemia Syndrome in Canadian Patients

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by persistent extreme hypertriglyceridemia as a result of lipoprotein lipase deficiency. Canada is an important region for FCS research due to the high prevalence rates. The burden of illness and quality of life of Canadian patients, however, have been inadequately addressed in the literature. The objective of this study is to understand the burden of illness of FCS on Canadian patients’ lives. Authors Daniel Gaudet, Michael Stevenson, Nelly Komari,…

Read Now

Scientific Publications

Hypoactive Sexual Desire Disorder (HSDD) is not ‘Female Erectile Dysfunction (ED)’: Challenges with the Characterization of HSDD in Women Based on a Systematic Literature Review

Hypoactive sexual desire disorder (HSDD) in women has been viewed inaccurately by some in the medical and payer community as analogous to erectile dysfunction (ED) in men. This literature review aims to highlight the distinctions between HSDD and ED. Authors Sheryl Kingsberg, Shruti Nambiar, Swagata Karkare, Nandini Hadker, Michelle Lim-Watson, Laura Williams, Julie Krop Journal National Library of Medicine; Current Medical Research & Opinion; June 2020 View publication…

Read Now

Scientific Publications

Assessing the Real-World Inpatient Treatment Paradigm for Recurrent Clostridium Difficile

This analysis of real-world hospital data aimed to characterize the treatment regimens for inpatients experiencing rCDI, including both hospital- and community-acquired recurrence, and to compare these regimens to current treatment guidelines. Authors Gavin Miyasato, Hannah Li, Dushyant Katariya, Kevin Francis, Nandini Hadker Journal ISPOR Meeting; May 2020 View publication…

Read Now

Scientific Publications

Network Meta-Analyses of Real-World Evidence: A Systematic Review of Methods

Network meta-analysis (NMA) compares multiple health technologies when there is a lack of direct evidence with randomized controlled trials (RCT) alone. While supplementing RCTs with robust real-world evidence (RWE) in NMAs has become standard practice, NMAs of RWE alone are now being used to gain insights into the patient experience in clinical practice. This SLR aimed to assess the quality of published RWE-only NMAs and evaluate the statistical methods used to account for clinical and statistical heterogeneity. Authors Nambiar S,…

Read Now

Scientific Publications

Cost of Care Analysis for U.S. Patients with Prader-Willi Syndrome (PWS)

This study analyzed direct medical costs of PWS patients and compared these to non-PWS patients; cost variation between those receiving growth hormone (GH) and those not was also evaluated. Authors Justin Li, David Yin, Qian Meng, Abigail Silber, Sina Aghsaei, Kevin Francis, Nandini Hadker, Theresa Strong, Jennifer Miller, Merlin Butler, Ann Manzardo, Michael Yeh, Shawn Czado Journal ISPOR Meeting; May 2020 View publication…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.